Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 May 8;4(5):e001614. doi: 10.1161/JAHA.114.001614

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Cardiomyopathic proteome restitution. A subset of 48 proteins was reversed by iPS cell therapy, significantly altered [red, TAC-iPS(+)] in the opposite direction to their initial significant change in response to disease [gray, TAC-iPS(−)], including 18 proteins (*) with established links to cardiac adverse effects (A). The 48 reversed proteins account for 44% (48 of 109) of resolved cardiomyopathic proteome changes (B) and 86% (18 of 21) of cardiomyopathic protein changes having canonical links to adverse cardiac outcomes (C). In response, all adverse cardiac outcomes predicted by hypergeometric overrepresentation analysis of the initial cardiomyopathic proteome (gray) were nullified by cell therapy (red; D). iPS indicates induced pluripotent stem; TAC, transverse aortic constriction.